Podcasts about icer

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

Read along with our transcript.What if the solution to winter's infrastructure corrosion and environmentally benign home sidewalk de-icing was an invasive starfish being thrown back into Korea's coastal waters? Hando Choi, president of Star's Tech, joins the conversation to explain how one region's invasive species problem can become another's environmental breakthrough. The company developed ECO-ST, a de-icing product made from starfish skeletons that not only melts ice faster than conventional rock salt but also reduces the chloride pollution that causes billions of dollars in damage to roads, bridges, and vehicles every winter.Meanwhile, in Korean waters, the Northern Pacific sea star has become such a menace to shellfish aquaculture that the government purchases 3,000 to 4,000 tons annually to control populations. Stars Tech upcycles about 10% of that collected material, extracting the porous calcium carbonate structures that give starfish their shape and their remarkable ability to store and release chloride. The technology began as a high school science project when founder and chief scientist Seungchan Yang experimented with natural pore structures to control ion release, eventually connecting that research to the negative impacts of conventional deicers while studying at Seoul National University.The economic case is compelling once you factor in the full cost of ownership. While ECO-ST runs $465 to $650 per ton compared to $100 to $150 for commodity rock salt, salt itself accounts for less than 5% of most winter maintenance budgets. The Isaac Walton League of America estimates that infrastructure damage from road salt ranges from $30 to $300 per ton used. Stars Tech's simulations based on U.S. municipal data show ECO-ST can deliver up to 5,000% ROI over time when lower infrastructure maintenance costs, fewer reapplications, and ESG compliance benefits are factored in.ECO-ST is available on Amazon in the U.S. and Canada, with retail partnerships launching this winter. You can learn more about Stars Tech at starstech.co.Subscribe to Sustainability In Your Ear on iTunesFollow Sustainability In Your Ear on Spreaker, iHeartRadio, or YouTube

Professor Tim Murithi in this interview explains how Africa has always been a central part of the UFO encounter phenomenon. Murithi is an internationally respected advocate for peace, a member of the Society for UAP Studies, and an affiliate of the International Coalition for Extraterrestrial Research, or ICER. He is also head of the Peacebuilding Interventions Programme at the Institute for Justice and Reconciliation in Cape Town, South Africa, as well as the Extraordinary Professor of African Studies, at the Centre for African and Gender Studies, University of the Free State, also in South Africa. Murithi has more than 25 years of experience in the fields of peace, security, international justice, governance, and development, and has become an avid scholar of the UAP phenomenon, African folkloric connections to UAP, and the global politics of disclosure. We discuss UFO history in Africa, including the rather prescient scientific knowledge of the Dogon Tribe, E.T.-related Egyptian myths, and the Ariel School event in Zimbabwe, including its investigation by Harvard psychiatrist Dr. John Mack. We drill down on how knowledge that we are not alone may impact the state of our struggling world. Finally, we explore the need for a truth-and-reconciliation movement — such as the one deployed in South Africa to end apartheid — to finally break through what UFO scholar Richard Dolan calls “the truth embargo.”

President för ICER:s verkställande styrelseGrundare av Italiens Centro Ufologico Nazionale (1967 – idag)Redaktör för CUN:s UFO Magazine (1967 – idag)Medarbetare i FSR och Ray Palmers Flying SaucersMedlem i NICAP samt Italiensk representant för APRO, MUFON och CUFOSInternationell författare (över 40 böcker)Arrangör av den årliga UFO World Symposium (San Marino, 1993 – idag)Medgrundare av Amateur Astronomer Montelupo Group (Florens)År 1997 upptäckte Maura Tombelli från Montelupo-gruppen en asteroid som fick namnet PINOTTI (12470–1997 BC) i Minor Planet Catalogue.Har organiserat över 100 konferenser (varav 90 internationella)Internationell föreläsare inom alla områden av ufologiFramträtt i TV, radio och dokumentärer

In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in pharma. We unpack how Generalized Cost-Effectiveness Analysis (GCEA) builds on traditional Cost-Effectiveness Analysis (CEA) and differs from ICER's model. The conversation explores what these approaches mean for pricing, access, and patient voice—especially in rare and high-innovation settings. Through the Cidara CD388 flu drug case, we discuss how assumptions shape value and trade-offs from manufacturer and patient perspectives. The episode highlights how evidence, incentives, and outcomes align—or conflict—in today's system, and what reforms could better connect value frameworks to affordability and equitable access. Richard Xie, Senior Health Economist, RA Capital Management Gunnar Esiason, MBA, MPH, Senior Director, Head of Patient Engagement and Patient-Centered Innovation, Raven (RA Capital Ventures) Patient-Centered Value Assessment Models Episode 26: Sarah Emond, ICER Peter Kolchinski, The Great American Drug Deal NICE (UK) CDA (Canada) Australia CHAP Trikafta ICER Report on Cystic Fibrosis No Patient Left Behind GCEA Calculator Boomer Esiason Foundation Aurora Biosciences Most-Favored-Nation Drug Pricing Order Questions or comments? Email comments@prescriptionforbetteraccess.com. Follow us on X, LinkedIn, YouTube, and Threads.

Uncle Neds Squadron 11-11-50 Ned talks about de-icer boots

In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was appointed to lead the organization following the retirement of Dr. Steven Pearson. Sarah outlines her vision for ICER and the priorities for strengthening the framework and collaboration to achieve their mission of evaluating the comparative effectiveness of new medicines. Sarah also discusses ICER’s efforts to expand patient engagement and the evaluation of payers to ensure fair access to medicine. Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER) Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER) Barriers to Fair Access Report Gross-to-Net Bubble Pharmacy Benefit Managers (PBMs) Humira biosimilars Institute for Clinical and Economic Review (ICER) 340B Drug Pricing Program Questions or comments?Email us at comments@prescriptionforbetteraccess.com.Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

Patient rights: do you know about the rights you have in regard to healthcare? There is a lot of information for you that Sara and Thayer serve to you here, in terms you can understand.  They both work for the Partnership to Improve Patient Care, or PIPC (a coalition).Sara Traigle van Geertruyden is the Executive Director at PIPC. Thayer Roberts is the Deputy Director.  Sara, an attorney, joined PIPC in 2011 and serves at the firm, Thom Run Partners.  Sara focuses policies to advance a patient centered health system, from patient engagement in research to driving outcomes that matter to patients in healthcare payment and delivery.  Sara is a healthcare and welfare policy expert with over 25 years of experience, beginning her career on Capitol Hill working for former Senator John Breaux (D-LA) from 1996-2003, and later as an attorney at the law firm Patton Boggs.  Thayer joined PIPC in 2019. Thayer works with PIPC's diverse membership of patients, healthcare providers, researchers, and other groups to ensure that patient centricity is at the core of the nation's health care system.  Thayer has expertise in health care value assessments and their implications on patients and people with disabilities and continues to engage in this topic both at the Federal and State level. Chair of PIPC: (From their website) Tony Coelho is a former United States congressman from California, and primary author and sponsor of the Americans with Disabilities Act. Tony was elected to Congress in 1978 and served for six terms until 1989. He served on the Agriculture, Interior, Veterans Affairs, and Administration Committees during his tenure, specializing in disabled rights. In 1986, Tony was elected House Majority Whip. As the chief vote counter for his party, Tony oversaw a series of Democratic victories in the House on measures ranging from the budget to cutting off funds for the war in Central America. Tony was the original author of the Americans with Disabilities Act, signed into law by President George H.W. Bush. By 1994, the U.S. Census Bureau reported that some 800,000 more people with severe disabilities had found employment than were employed when the bill was first enacted. Tony currently serves as the DNC Disability Council Chair, seeking to ensure that the political process is accessible to people with disabilities. President Bill Clinton appointed Tony to serve as Chairman of the President's Committee on Employment of People with Disabilities, a position he held from 1994 to 2001. He also served as Vice Chair of the National Task Force on Employment of Adults with Disabilities. In 1998, Clinton appointed Tony as the United States Commissioner General at the 1998 World Expo in Portugal. Clinton also appointed Tony as Co-Chair to the U.S. Census Monitoring Board, a position he held until his appointment as general chairman of the Gore presidential campaign.Sara and PIPC work with nonprofit organizations, like The Bonnell Foundation to help us to understand and keep track of all the legislation on the books, and coming down the pipeline. To contact PIPC go to: https://www.pipcpatients.orgTo find PIPC on social media check them out at: @PIPCpatients (on twitter and LinkedIn)Another resource Sara and Thayer suggest: https://www.patientaccessproject.orgAcronym's used during this podcast: Prescription Drug Affordability Board (PDAB)Rare Disease Advisory Council (RDAC)National Association for State Health Policy (NASHP)Institute for Economic and Clinical Review (ICER)Equal Value of Life Year Gained (EVLYG)HR 485 Protecting Healthcare for all Patients Act   Read it here: https://www.congress.gov/bill/118th-congress/house-bill/485 Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

In this episode, Joe interviews Ingmar Gorman, Ph.D.: clinical psychologist and co-founder and CEO of Fluence, a psychedelic education company. Gorman served as a co-principal investigator and study therapist on MAPS' Phase II and III clinical trials for MDMA-assisted psychotherapy for PTSD, and works with drug sponsors: training, developing the components for clinical trials, and designing therapy manuals. With his insider's perspective, he discusses the reasons why he believes the FDA rejected MDMA-assisted psychotherapy for PTSD: from ICER's 2.1 section of the report giving legitimacy to allegations they don't have the authority to research, to Lykos not being able to defend some accusations due to confidentiality, to the damage caused over time (which likely influenced the decision) from attacks against Lykos from dissenters. He discusses: How, despite abuse claims, the main allegations in the report were actually about the mishandling of data or influence of investigators on participants The complications of needing to follow study frameworks: Should your adverse experience be in the report if it happened outside the study window? How easily opposition can attack and demonize a faceless company, while forgetting the humanity of the people behind it Inner healing intelligence and the proposition that people have been indoctrinated into this concept by MAPS The need for journalists to research more and not just jump on a narrative and more! For links, head to the show notes page. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.EPRO, or electronic patient-reported outcomes, is increasingly used in clinical trials to improve data accuracy, patient compliance, and reduce administrative burdens. Swing Therapeutics achieved 98% patient compliance in their pilot trial using EPRO, leading to an FDA de novo marketing authorization. EPRO boosts efficiency, saves costs, and improves trial outcomes.The BioSecure Act, which restricts contracts with certain Chinese companies in the US biotech industry, has advanced in the House but still needs Senate support. Bain Capital closed a $3 billion biotech fund and has been acquiring startup companies. Centessa's sleepiness drug showed promising results, lifting the company's shares. New data raise doubts about AstraZeneca and Daiichi's cancer treatment successor. Candid aims to prove the worth of bispecifics in autoimmune diseases.Roivant Sciences has acquired the rights to develop and commercialize Bayer's pulmonary hypertension drug, Mosliciguat, under an in-license agreement worth up to $294 million. Roivant has created a new "vant" called Vant to focus on this project. The Biosecure Act has passed through the U.S. House of Representatives and is set for a Senate vote. AstraZeneca and Daiichi Sankyo's Dato-Dxd failed to significantly improve overall survival in Phase III NSCLC trials, but there is still potential for FDA approval. Terns Pharmaceuticals announced a $125 million raise following positive Phase I data for their oral GLP-1 candidate for obesity.Old Navy is celebrating its 30th anniversary by throwing back to the '90s in a new collection and campaign to enhance its iconic brand. PayPal has launched its largest-ever US ad campaign featuring Will Ferrell, promoting the use of PayPal for both in-store and online transactions. Angela Zepeda, former Hyundai CMO, has been appointed as the global head of marketing for X. Pizza Hut is turning TikTok content into real-world currency for a promotion in the UAE, while Target is targeting pet owners with a collection designed by "fur-fluencers." Marketers are leveraging AI on mobile platforms and genAI is impacting marketing strategies.Merck's Keytruda, a leading immuno-oncology drug, has been highly successful in treating various cancers and has become the world's top-selling drug. However, determining the true value of a drug like Keytruda involves more than just sales numbers. U.S. drug pricing watchdog ICER tracks pricing decisions and their impact, but the industry is exploring new methods to factor in aspects like disability and income disparity. A new formula that considers "standard of living" is being explored to offer a different perspective on pricing in the pharmaceutical industry. As Keytruda celebrates its 10-year anniversary on the market, the impact of this cancer drug and other immunotherapies is being analyzed, along with the future direction of the field.

In this episode, Joe interviews Erica Rex, MA: award-winning journalist, past guest, thought leader on psychedelic medicine, and participant in one of the first clinical trials using psilocybin to treat cancer-related depression. She tells the story of her recent harrowing experience, brought on by 6 times the amount of Syrian rue that was recommended: from entities threatening her, to a sense of terror she was going to die, to finding her way out of it with time, and most importantly, context to process and a strong support system. She and Joe emphasize the reality that bad trips can happen at any time, with any dose, for any reason, and that – if you can make your way through the experience without being traumatized – you can learn a lot about yourself during those states. She discusses: Methods to help others having a bad experience Her skepticism about psychedelic therapy being in a medical context at all Her thoughts on the recent ICER recommendation against approving MDMA and the multiple topics not addressed Possible complications from MDMA use nobody talks about, from cytotoxic effects to even sudden-onset psychosis The pathologizing of anything outside the ordinary, to the point that we're trying to suppress natural human emotions and reactions and more!  For links, head to the show notes page.

In this compelling episode of The Psychedelic Report, Dr. Dave Rabin delves into the evolving landscape of psychedelic-assisted therapies with special guest Jon Lubecki, a veteran and prominent advocate for such treatments in Ukraine. The discussion centers on the recent FDA advisory committee setback, which resulted in a 10 to 1 vote against MDMA-assisted therapy due to lingering concerns about its safety and efficacy, particularly in post-treatment activities like driving. Jon provides a nuanced analysis of the hearing, pointing out significant conflicts of interest among some opponents who failed to disclose their affiliations with competing therapies like psilocybin and ketamine. He also examines the critical role of influential organizations such as ICER and Symposia, whose biased reports have swayed public and regulatory opinions against MDMA trials. With a fervent focus on the broader implications for mental health, especially for veterans suffering from PTSD, Jon underscores the inadequacy of current treatments and the transformative potential of MDMA-assisted therapy. He shares his personal journey from struggling with PTSD to becoming a leading advocate, passionately calling for the democratization of access to these promising therapies, transcending political and social boundaries.Instagram: https://www.instagram.com/jonathanlubecky/Web: www.mdmaptsd.orgTwitter: https://twitter.com/DrDavidRabinInstagram: https://www.instagram.com/drdavidrabinWeb: https://www.drdave.io/Web: www.ApolloNeuro.comCongressman Dan Crenshaw speaks out on the MDMA-assisted therapy controversy and the anti-Veteran agenda : https://www.instagram.com/reel/C8zsu2Wu7M0/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA==

In today's episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison  talk about the recent FDA psychopharmacologic drugs advisory committee meeting that resulted in a majority vote against the approval of MDMA-assisted therapy for PTSD based on MAPS/Lykos study data. They discuss what the committee's concerns were, the Institute for Clinical and Economic Review's (ICER) criticisms of the studies, the challenges of conducting psychedelic clinical trials, functional unblinding, how research and rater bias affects study data, and much more.https://psychedelicalpha.com/news/exclusive-therapists-and-trialists-from-lykos-phase-3-mdma-assisted-therapy-studies-push-back-on-icers-critical-draft-reportLearn more about our podcast at https://numinus.com/podcast/Learn more about psychedelic therapy training opportunities at https://numinus.com/training/Learn more about our clinical trials at https://www.numinus.com/clinical-trials Learn more about Numinus at https://numinus.com/Email us at ptfpodcast@numinus.com Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/

Host Fred Goldstein Invites Sarah Edmonds, President and CEO of ICER to discuss ICERs, Health Technology Assessments and determing value as we seek to move to a value based healthcare system. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Curious about the forces driving healthcare pricing and access? Join us for an enlightening conversation with Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah's upbringing in a family passionate about policy and social justice laid the foundation for her impactful career in health policy. We explore her educational journey from Smith College to Brandeis University's Heller School, and how her professional experiences in clinical research and biopharmaceutical consulting shaped her path to ICER.Unravel the complex world of health technology assessment (HTA) in the US as Sarah breaks down the challenges and opportunities within a fragmented healthcare system. ICER's pivotal role in evaluating new medical technologies is discussed in depth, including its interactions with international agencies like the UK's NICE. Sarah sheds light on ICER's evolution from a small initiative within Mass General Hospital to a powerful voice in global HTA practices, emphasizing the importance of fair pricing, patient access, and sustainable innovation funding.Equity in healthcare takes center stage as Sarah introduces ICER's updated value assessment framework. Learn about new tools like the clinical trial diversity rating and the Health Improvement Distribution Index (HIDI) designed to promote representation of diverse populations in clinical trials. We also tackle the high costs and value-based pricing of innovative treatments, including gene and cell therapies, and the necessity of evolving payment systems to ensure continuous innovation. Tune in to gain a comprehensive understanding of the pressing challenges and future directions in healthcare pricing, equity, and access.Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Sarah Emond (President and CEO, ICER) delves into the efficacy of gene therapy in enhancing patient outcomes and discusses the necessary adjustments the healthcare industry must make to accommodate the cost.

In this episode, Pam Divack sits down with Sarah Emond, President and CEO of ICER (the Institute for Clinical and Economic Review), an independent non-profit research organization that evaluates the evidence on the clinical and economic value of prescription drugs, medical tests, devices, and health system delivery innovations. They discuss the history of ICER and how it collaborates with stakeholders across the healthcare ecosystem, the key trends and industry pressures giving rise to an increased need for value assessments and comparative effectiveness research, how ICER is working to improve the US Healthcare System, and why this work is critical for aspiring healthcare leaders to track.

This conversation touches on two important subjects: the impact of different potential resmetirom prices on the size and structure of the treatable MASH population, and the impact GLP-1s are having (and will have) on clinical trial recruitment and basic patient treatment. It starts with Naim Alkhouri expressing concern over the $39-52K price he has heard for resmetirom, which ICER has deemed cost-effective. He mentions another paper that says a price of $19,000 would be cost-effective. To Naim, this magnifies a question that is already quite widely considered: when to prescribe resmetirom vs. a GLP-1 agent. He discusses some patient factors that might go into his decision. Naim describes ways that GLP-1 use, which can be sporadic or episodic, is affecting clinical trial recruitment. Ian Rowe discusses the current use of GLP-1s in the UK and suggests that if the price for resmetirom is high enough, GLP-1s will receive significant use. Naim Alkhouri shifts direction slightly, from discussing current GLP-1s to exciting recent clinical trial report. He focuses on two: survodutide from Boehringer Ingelheim and efruxifermin from Akero Therapeutics. Recent exciting results from BI and Akero suggest to Naim and others that the future for drugs is bright. Ian Rowe anticipates a significant amount of co-prescription of GLP-1s and resmetirom in this population. GLP-1s have already demonstrated clear cardiovascular, weight loss, and HbA1c-lowering benefits. To Ian, that creates sufficient motivation to prescribe GLP-1s to multimorbid patients with diabetes, obesity and most likely MASLD or MASH. To him, the price of resmetirom will have a tremendous impact on how often UK physicians rely on GLP-1s alone.

EPISODE #1017 UK PILOTS REPORTING UFOS Richard speaks with a magazine editor,researcher and international UFO lecturer who has launched a new UAP reporting platform for military, commercial, and civilian pilots in the United Kingdom. GUEST: Gary Heseltine is a former RAF Police and British Transport Police officer. He was a detective for 19 years and a former advanced interviewer of suspects and witnesses. In 2002 he launched an unofficial national police database for British police officers to report and collate their UFO/UAP reports. In April 2013 following his retirement from the police he launched UFO Truth Magazine (bi-monthly ezine). In 2021 he was one of the co-founders of ICER, the International Coalition for Extraterrestrial Research. He currently holds the position of Vice President. ICER is an international NGO comprising scientists, academics and leading UFO/UAP researchers with national representatives in the 30 countries. In February 2023, he published his first book 'NON-HUMAN The Rendlesham Forest UFO Incidents: 42 years of Denial' following a five-year re-investigation of Britain's most famous UFO case - The Rendlesham Forest Incident (Only on Amazon) In December 2023 he founded UK Pilots Reporting UAP which went 'live' on 12/02/2024. WEBSITES: https://www.ukpilotsreportinguap.co.uk http://prufospolicedatabase.co.uk https://www.ufotruthmagazine.co.uk BOOK: NON-HUMAN: The Rendlesham Forest UFO Incidents: 42 Years of Denial BIRCH GOLD GROUP - The Precious Metal IRA Specialists Diversify a portion of your savings into GOLD with Birch Gold Group. Gold is your hedge against inflation, and Birch Gold makes it EASY to own. Text STRANGE to 989898 and get your free info-kit on gold, then talk to a precious metals specialist on how to protect your savings from persistent inflation with gold. Text STRANGE to 989898 now. THE DEAD FILES On The Dead Files, physical medium Amy Allan and retired homicide detective Steve DiSchiavi solve unexplained paranormal phenomena in haunted locations across America. LISTEN TO THE DEAD FILES WHEREVER YOU GET YOUR PODCASTS BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit Use the discount code "Planet" to receive one month off the first subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

Three guests from a recent radio show - J M DeBord on some new research about external interactions with dreaming people... Gary Heseltine from ICER on a new initiative to help pilots report UAP sightings... And Glenn Steckling talks about his family's long involvement with the work of George Adamski - world-famous 20th Century Ufologist and contactee...

This conversation is part of a March, 2023 interview between co-hosts Louise Campbell and Roger Green and Jeff McIntyre of Global Liver Institute, one of the guests on the S5 E2 panel. This particular conversation focuses largely on Jeff's insights around the imminent anticipated drug approvals of obeticholic acid (which was withdrawn several months later) and resmetirom (whose PDUFA date is next month). Jeff's analysis includes mixed levels of enthusiasm around a draft report from ICER which includes pricing estimates for these drugs. The contention lies in the draft's reference to NASH as a non-progressive disease - a position which the panelists readily refute. Jeff's positive note is that the report carefully considers patient perspective and he was able to participate as an expert reviewer.The conversation shifts to speculations around the future standard for noninvasive testing and biomarkers. Jeff emphasizes the “need for a noninvasive that can be scaled with the least amount of burden to primary care providers and the patient populations that need them.” Roger Green points to the various guidelines' referral to FIB-4 as such a test. This summons quote of Quentin Anstee's repeated admonition that “we not let the perfect be the enemy of the good.” For whatever shortcomings of FIB-4, if it can be done now and it's two generations of successive approximation of what we've had before.As the session winds down, Louise Campbell asserts further comments around the ICER draft and NASH as a progressive disease. She recollects the podcast's recent conversation with Tim Jobson, founder of Predictive Health Intelligence, (S4 E5) which discusses developing a simple tool to identify patients at risk of liver disease by analyzing the results of blood tests given throughout their lives.

As it turns out, UFOs don't just land in America! In this episode with Thiago Luiz Tichetti we take a good look at Brazilian Ufology. Then journey with us back to the US as we discuss the recent events in Miami 2024. Was it just reckless teens? Was it ETs? Or is there something else behind all this? Find out in this episode. Then be sure to stick around for the end for an interesting discussion about the government's involvement in Steven Spielberg's famous film E.T. Here at First Contact we believe that the power to initiate contact with non-human intelligence is in your hands! Activate your ability to connect with the 5D Empire Vault. Here you will find 100+ Frequency Activations to activate your Merkaba Lightbody, access your Multidimensional Inner Heart, Quantum leap your abundance, and more. Join the 5D Empire Vault today: https://go.eeshapatel.com/5demembervault About Thiago: Thiago Luiz Ticchetti, whose father was a pilot in the Brazilian air force, has been researching the UFO phenomenon for almost 30 years. He is the National Director of MUFON in Brazil, STAR TEAM and ERT MUFON member, Delegate of ICER in Brazil, Director of CIFER, and president of the Brazilian Commission of Ufologists (CBU). Thiago is also co-editor and columnist for Revista UFO magazine and columnist for UFO Truth magazine. He has published dozens of articles for UFO Magazine and foreign publications. Author of 14 books: “Quedas de UFOs I", "Quedas de UFOs II", “Guia da Tipologia Extraterrestre”, "Guia da Tipologia Extraterrestre - 2ª edição", "Guia da Tipologia Extraterrestre - 3ª edição", "Guia da Tipologia dos UFOs", “Arquivos UFO: casos ufológicos - Volume I”, "Arquivos UFO: casos ufológicos - Vol. II", "Arquivos UFO: casos ufológicos - Vol. III", "Universo Insólito: livro de bordo - Parte 1 e 2", "UFO Contacts in Brazil", "Contacts OVNIs au Brésil" and “Cartas Para Claudeir Covo”. About Eesha: Eesha Patel is a Galactic Contact Expert. Her work has been featured in prominent media including Channel 10, Channel 7, Radio Fremantle and Coast to Coast AM with George Noory. Eesha is a trailblazer and thought leader in the field of galactic consciousness. Her work has received endorsements from prominent researchers in UAP/UFOs, including Professor Abraham Loeb. Eesha is host of the podcast First Contact which is leading the conversation around how humanity can peacefully awaken and connect with our intergalactic family. Eesha leads visionary entrepreneurs into discovering their own galactic soul family through her bespoke and luxury galactic experiences. You can connect with Eesha Patel at www.eeshapatel.com. To invite Eesha for an interview please connect with her at contact@eeshapatel.com.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today we have a packed episode with news from the healthcare industry. Let's dive in.Integra is set to acquire J&J's Acclarent for $275 million, making them a market leader in ENT procedures. Illumina is divesting its acquisition, Grail, following orders from regulators. Zimvie has received clearance for its spinal fixation system through a collaboration with Brainlab. Crispr Therapeutics and Vertex Pharmaceuticals have developed a sickle cell disease therapy using Crispr technology. Heart device makers are investing in left atrial appendage closure as a potential $6 billion market by 2030. Activist investor Engaged Capital has taken a stake in Nevro.Pfizer is planning to deepen its cost cuts after sales forecasts missed expectations. Vertex Pharmaceuticals is building a case for a non-opioid pain drug. Doctors at the ASH meeting have praised new sickle cell gene therapies. Biotech mergers and acquisitions are picking back up, with Astrazeneca's acquisition of Icosavax being the first large buyout of a vaccine developer since GSK's purchase of Affinivax. Tome Biosciences has debuted with $213 million in funding.Centene attempted to ease concerns about the potential overhaul of the ACA. KKR is reportedly in talks to buy a stake in Cotiviti. Google has revealed new generative AI models for healthcare called MedLM. Cerner is expected to be a growth story for Oracle after this fiscal year. There have been reports of hackers having access to patient information in a cyberattack on a New York hospital.Pfizer's stock price dropped after providing its full-year 2024 guidance. Johnson & Johnson and Genmab released data from a phase III study of their darzalex faspro-based quadruplet therapy. The FDA has created the Genetic Metabolic Diseases Advisory Committee. Biopharma companies are shifting their advertising budgets away from Xplus. South Africa is moving towards greater local biopharmaceutical production.AstraZeneca is set to acquire vaccine maker Icosavax. The FTC has led Sanofi to terminate a drug research deal with Maze Therapeutics. Editas presented its gene therapy for sickle cell disease at the ASH23 conference. Tome Biosciences has debuted with $213 million in funding. Bristol Myers Squibb has paid SystImmune $800 million in a deal involving ADCs. AbbVie's Humira leads ICER's list of "unsupported" price hikes. Pfizer presented new data at the ASH conference.Bristol Myers Squibb has acquired the rights to develop SystImmune's bi-specific ADC. Pfizer's acquisition of Seagen has cleared regulatory hurdles. Sanofi has dropped its acquisition of Maze Therapeutics' Pompe disease drug. AstraZeneca has entered the RSV vaccine market with its purchase of Icosavax. Sino Biological has developed three HEK293 expression-based platforms.The Daily Dive newsletter from Marketing Dive highlights several key stories. Oscar Mayer and Mint Mobile are teaming up for a national campaign called "A Side of Bacon." Frito-Lay is reaffirming its commitment to diverse creators with a new campaign called "My Joy." IPG Mediabrands has struck a deal with Amazon for ad-supported streaming. The newsletter also includes an opinion piece on retail media networks and an upcoming virtual event on generative AI in marketing.The pharmaceutical industry is preparing for upcoming changes and challenges. The cost of medicine is expected to be a major debate point in the 2024 presidential election. Bristol Myers Squibb's Chief Commercial Officer discusses the industry's shifting approach. The article includes sponsored content from AstraZeneca, highlighting their expansion in blood cancer care. The text concludes with links to other resources and press releases.And that's all for today's episode. Stay tuned for more important news from the Pharma and Biotech world. Goodbye!

Terry Wilcox, Patients Rising CEO, along with Rick Chapman, the Chief Science Officer at the Innovation and Value Initiative, and Darius Lakdawalla, the Chief Scientific Officer at EntityRisk, hold a patient advocate event focused on the need to improve ICER; and the Patient Access and Affordability Project's new report on discriminatory formulary practices. Healthcare Policy Pop Episode: Biosimilars Slow Uptake (GRACE Model) Patient Access and Affordability Project Report: Equitable Access: Examining Discriminatory & Restrictive Practices in Prescription Drug Formularies  

Andy & Dan look through a few weeks of news including; New David Grusch interview with ICER Sean Kirkpatrick leaving AARO Greek/Roman God comments Ross Coulthart on February Shoot downs Much, much more Get in touch with the show; Twitter: @UFOUAPAM Facebook, YouTube & Instagram: "That UFO Podcast" YouTube: ⁠⁠YouTube.com/c/ThatUFOPodcast⁠⁠ Email: ⁠⁠UFOUAPAM@gmail.com All podcast links & associated links; ⁠⁠Linktr.ee/ufouapam⁠ ⁠⁠ThatUFOPodcast.com⁠⁠ ⁠⁠Linktr.ee/TheZignal⁠⁠ ⁠⁠UAPMedia.UK Don't forget to subscribe, like and leave a review of the show, Enjoy folks, Andy

BMS's acquisition of Mirati for up to $5.8 billion not only gives the big pharma a potential best-in-class KRAS inhibitor in a field that appears to be opening up, but also a clinical program against one of the hottest targets in precision cancer, PRMT5. On the latest BioCentury This Week podcast, BioCentury's editors discuss what Bristol Myers Squibb stands to gain from its acquisition of Mirati Therapeutics, which had rumors swirling about its potential takeout last week. BioCentury's editors also discuss their 4Q23 Public Markets Preview, including how private biopharma companies looking to go public in the next 12 months should be managing their path to that transition. Following last week's analysis of the companies leading the transition of CAR T therapies into the autoimmune space, BioCentury's editors also touch on the targets and technologies coming up behind the leading programs that could expand use of CAR Ts to a wider set of autoimmune indications. They also discuss takeaways from ICER's report on how CMS might approach drug price negotiation under the Inflation Reduction Act.

John O'Brien, President and CEO of the National Pharmaceutical Council, weighs in on ICER's latest update that we are calling a “faux update”; The American Enterprise Institute has released its perspective on last year's Inflation Reduction Act; and The National Institute on Minority Health and Health Disparities has officially designated people with disabilities as a population with health disparities. National Pharmaceutical Council Webpage: NPC Evaluates ICER's Revised 2023 Value Assessment Framework American Enterprise Institute Webpage: What Does the Inflation Reduction Act Mean for Patients and Physicians? National Institutes of Health Webpage: NIH designates people with disabilities as a population with health disparities  

With the Open Enrollment Period fast approaching, Levi Peterson, a Resource Coordinator for our Patient Helpline walks us through what everyone needs to know about Medicaid and Medicare eligibility, PPOs and HMOs, and how to pick a health plan that best fits your needs. We also discuss a so-called ICER update that doesn't do much updating and still doesn't help patients. Patients Rising Now Statement | ICER ‘Updates' are Thinly Veiled Strategy to Continue Discriminatory Tactics  ICER's Updated Treatment Assessment Still Ignores Patient Concerns    Need help? The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at the Patients Rising Helpline. Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent? Drop us a line: podcast@patientsrising.org The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest's current or previous employers.  

Bill Smith, Director of the Life Sciences Initiative at the Pioneer Institute, dives into the so-called update to ICER's value assessment framework; Congresswoman Cathy McMorris Rodgers explained earlier this year why she was against the QALY measurement; and Patients Rising Now along with several other groups have issued statements denouncing the ICER update. Pioneer Institute Webpage Patients Rising Podcast Episode: Healthcare Protections for Rare Diseases with Rep. Cathy McMorris Rodgers Patients Rising Now Webpage: Patients Rising Now Statement – ICER's ‘Updates' are Thinly Veiled Strategy to Continue Discriminatory Tactics National Pharmaceutical Council Webpage: NPC Evaluates ICER's Revised 2023 Value Assessment Framework – A Missed Opportunity for Patients and the Field Biotechnology Innovation Organization Webpage: ICER's updated treatment assessment still ignores patient concerns  

In the wake of Medicare's announcement of the first 10 drugs subject to price negotiations, Patients Rising CEO Terry Wilcox outlines the need for greater patient involvement in this process; Taylor Schwartz of Avalere explains a new white paper that analyzes the use of patient-centered outcomes in ICER reviews; CMS issues draft guidance on new Medicare Part D smoothing program. Patients Rising Calls on CMS to Engage with Patients in Drug Price Negotiations Patients Rising Now Comments: Medicare Drug Price Negotiation Program Guidance Memo CMS Webpage: Medicare Drug Price Negotiation Program Avalere Webpage: Use of Patient-Centered Outcomes in ICER Assessments

Today we welcome special guest Gary Heseltine to discuss his time in the Royal Air Force Police & His time as a Transportation Police officer. After retiring Gary created PRUFO or "Police Reporting UFO Sightings" which caters for serving & retired British Police so they can report there sightings. Gary is also the Founder & editor for the famous "UFO Truth" Magazine which we will discuss some of his work and how he came to be involved in the field of Ufology. Gary is now the current Vice President of ICER, and is currently working with Colonel Charles Halt to piece together the Rendlesham Incident, so we plan to discuss whats going on with that and what we can expect moving forward. So with that being said, Strap on Those Seat belts, were going for a Ride! - SPONSORED BY: "SPIRITUAL CONSCIOUSNESS: A PERSONAL JOURNEY" By: Kevin J. Briggs - GET YOUR COPY AT: www.KevinJBriggs.com GARY'S BIO: Gary Heseltine is served in the RAF Police between 1983-89 before joining the British Transport Police in 1989. He went on to have a 24-year career in the police, mostly as a Detective Constable who was also an advanced interviewer of suspects and witnesses. In 2013 he retired from the police early to launch UFO Truth Magazine, a bi-monthly ezine (www.ufotruthmagazine.co.uk). In 2020 he became the Vice President of the International Coalition for Extraterrestrial Research (ICER), a not-for-profit NGO with national representatives in 30 countries. In February 2023, after a five-year re-investigation of the Rendlesham Forest Incident he released his first book, NON-HUMAN The Rendlesham Forest UFO Incidents: 42 Years of Denial. UFO TRUTH MAGAZINE - www.ufotruthmagazine.co.uk Gary's Book - https://www.amazon.co.uk/NON-HUMAN.../dp/B0BVDF6W2Z/ref=sr_1 - SPONSORED BY: "SPIRITUAL CONSCIOUSNESS: A PERSONAL JOURNEY" By: Kevin J. Briggs - GET YOUR COPY AT: www.KevinJBriggs.com - DONATE/SPONSOR THE SHOW AT - https://paypal.me/JessePmufonFI - IT WILL HELP KEEP THE SHOW GOING, PLUS YOU GET A "SHOUT OUT" ON THE SHOW AND A PLACE ON THE WEBSITE! CONTACT ME: TWITTER - @AATPEAK WEBSITE - UFOENCOUNTERSWORLDWIDE.WORDPRESS.COM EMAIL - UFOENCOUNTERSWORLDWIDE@GMAIL.COM --- Support this podcast: https://podcasters.spotify.com/pod/show/ufoencountersworldwide/support

Avalere releases a study focused on ICER assessments and whether or not they take into account the patient experience when creating their reports; Wayne Winegarden, a Senior Fellow with the Pacific Research Institute explains how new Humira biosimilars have affected the market and their possible effect on PBMs; and drug shortages are worsening, and this time they're affecting diabetes medications. Avalere Webpage: Use of Patient-Centered Outcomes in ICER Assessments Patients Rising Now Comments Fierce Pharma News Article: Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval  

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.This conversation continues focus on the concerns around appropriate data collection and analysis to discover the best path forward. Will describes the need to collect the kinds of data that will assess the value of the process and the right way to execute as processes are built and implemented. Vanessa agrees, but asks that we not let the perfect be the enemy of the good and that we keep in mind how many patients with advanced fibrosis are not getting diagnosed today and need the support of this program. One point that clearly emerges in dialogue with Will is that other countries will look to NICE and the UK experience to inform their own decisions. This only amplifies the need to collect data well and wisely. Louise states that she would also like to see data about the effect of this initiative on related metabolic conditions. She likens FibroScan scoring to dropping a pebble in a pond and seeks to explore the ripples it makes in related diseases and conditions, particularly for endocrinology and cardiology. Roger remarks on how refreshing it is to hear a conversation where multiple stakeholders are aligned to find the best approach to the disease. He goes on to contrast this topic to the role of ICER. Finally, Roger asks questions around Louise's pond metaphor and mentions comments that Stephen Harrison and Mazen Noureddin made last autumn that had suggested that FAST may be a better first line test. Will suggests that many questions need to be answered before determining the accuracy of the tests or what the best way to perform them is.If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Sheryl Gottschall has had a life-long interest in the paranormal and began studying the phenomenon of Near Death Experiences (NDEs) in 1980, soon after becoming a member of the International Association of Near Death Studies (IANDs). In 1995 she hosted IANDS co-founder, Dr Ken Ring while he was on tour in Australia presenting research for his future book Mindsight: Near Death and Out Of Body Experiences In The Blind. Little did she know she would experience an NDE for herself the following year during a serious decade long illness. Sheryl's interest in NDEs paralleled her interest in UFOs, so in 1988 she joined the Brisbane based organisation, UFO Research Queensland (Australia). At that time the organization was soon overrun with ever growing reports of alien abduction experiences so in 1992 Sheryl, with her late husband Dr Martin Gottschall, established the first close encounter support group in Brisbane which they facilitated over the years, on and off, as needs arose. Expanding her interest in the UFO subject and the move towards disclosure, Sheryl was invited to fill the role of the Australian representative for the International Association of Extra-terrestrial Research (ICER) which launched in May 2021, and is the first truly international group of UFO researchers from 30 countries working together. Sheryl loves media and has been a weekly guest on the Spooky Action radio show (2018), co-hosted the Strange Encounters radio show (2019), the Insomnia radio show 2022 (current) and now co-hosts the fortnightly show – Strange Encounters Downunder. These shows have served as a further catalyst for members of the public to report their experiences to her, many of who have never shared them before. https://www.youtube.com/@UFOResearchQueenslandThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4602609/advertisement

Donna Cryer joins Jörn Schattenberg, Louise Campbell and Roger Green for an impactful episode which weighs the complexities of competing needs across all Fatty Liver stakeholders. The session expands discourse on the recently discussed ICER draft report to consider a developing landscape around nomenclature consensus and other important and impending decisions. Critically, the group grapples with challenges associated with honoring the precedence of patient-centricity.Donna opens this conversation with several calls to action for patient advocacy in the NASH community. Her first recommendation is to recruit different disciplines to administer and evaluate an impact report regarding nomenclature consensus. Next, and more broadly, she asks all stakeholders to consider how to genuinely and effectively build an inclusive advocacy community. Roger asks Jörn what he believes to be realistic that the field can do for these aims today. First, Jörn notes that many different societies can agree on what is considered to be a severe patient and what an unfavorable outcome is in terms of liver disease. He goes on to say that with therapies in the pipeline and tests like FIB-4 available and widely implementable now, we have indeed come a long way as a field. The risks he perceives with topics such as the ICER draft report and nomenclature consensus revolve around slowing, detouring or dismantling the tremendous progress that has been made. As the session wraps up, Donna offers her thoughts on where this is all heading. Listen to the full feature to engage with these impactful moments. If you enjoy the episode, have questions or interest around endocrinology and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Donna Cryer joins Jörn Schattenberg, Louise Campbell and Roger Green for an impactful episode which weighs the complexities of competing needs across all Fatty Liver stakeholders. The session expands discourse on the recently discussed ICER draft report to consider a developing landscape around nomenclature consensus and other important and impending decisions. Critically, the group grapples with challenges associated with honoring the precedence of patient-centricity.This final conversation begins with Roger's note that while patient stories are driven with emotion and impact, the actual patient journey through diagnosis to treatment can unfortunately be a mechanistic and confusing process. With this in mind, Roger asks how do we bring a more holistic sense of what it means to be a patient or patient advocate to all of these issues discussed as they continue to amplify in a bigger, broader way. Donna's moving response and the various final thoughts from the other panelists encapsulates the need for patients to be respected for the professional skills they possess which can contribute real impact on how the field moves forward in a stronger, more multi-disciplinary fashion. Listen to the full segment to hear the moving statements.If you enjoy the episode, have questions or interest around endocrinology and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On! 

Donna Cryer, CEO of the Global Liver Institute, previews liver disease patient advocates' testimonies ahead of an ICER meeting on two new treatments; the House Health, Employment, Labor and Pensions Subcommittee holds a hearing titled Reducing Health Care Costs for Working Americans and Their Families; the House Energy and Commerce Health Subcommittee hosted its own meeting about the importance of addressing unaffordable costs in healthcare; and correspondent Kathi Luis lives in Michigan's 9th district and sees how Copay Accumulator programs are hurting patients. Global Liver Institute Webpage CNBC News Article: FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease Patients Rising Webpage: Patients Rising Stories

In this episode, we interview Dr. Steven Pearson, the founder and President of the Institute for Clinical and Economic Review (ICER). Over the past 16 years, ICER has evolved from a Harvard research program to the independent authority on cost-effectiveness and value of new drugs. Dr. Pearson has been an advocate of “Fair Pricing for Fair Access” and in January 2023, ICER published their 2nd Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage. Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER) Institute for Clinical and Economic Review (ICER) Barriers to Fair Access Report Gross-to-Net Bubble Like this episode and want to hear more? Check out our past episodes here! Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

Gary Heseltine from UFO Truth Magazine and ICER talks about his fresh investigation of the Rendlesham Forest UK/US airbase "close encounter" of December 1980 - and his new book "Non Human" (available on Amazon) Plus - an exclusive interview with a retired US serviceman - James Stewart - who says he experienced deeply disturbing events at the Woodbrige base Rendlesham) one year before...

SHOW NOTES: Kitchen Island Design: Add extra food prep space with a versatile kitchen island that's affordable and user-friendly. Driveway Markers: Get ideas for eye-catching driveway markers to add curb appeal and increase home safety. De-Icing Tips: Find out how to quickly thaw a frozen windshield with this easy DIY solution. Plus, answers to your home improvement questions. Home Addition ROI: Finished basement or second-floor addition: which one offers a better ROI? We think Matthew's home will gain more value by adding bedrooms and bathrooms on a second floor. Rodents: Kathryn wonders if an ultrasonic device would help control the mice in her basement. Along with baits and poison, it would be more effective to eliminate nesting areas, plug up any openings, and avoid leaving any food or water in the house or garage that could attract pests. Gutters: Joe's roof shingles don't extend far enough to direct water into the gutters. We suggest using a flat bar to pry up the edges and insert flashing under the shingles to create a bridge to the gutters. Countertops: Is there a way to remove scratches in a Corian countertop? Gayla can try a deep cleaning product to make them less obvious or have a professional lightly sand and repolish the surface. Deck Cleaning: What's the best way to clean algae and mold from a pressure-treated wood deck and a stone patio? Bill needs a pressure washer with a bleach solution to remove the stains. Wallpaper Removal: Jan wants to remove a layer of wallpaper liner without damaging the drywall. If it's adhered well, she should be able to add a textured surface right over it. Fascia Board: Is it possible to remove a rotted fascia board without removing the spacer and gutter? It will all need to come off, but then Derwin can replace the wood fascia with a cellular PVC board that will last without rotting. Dry Rot: What causes dry rot and how to tell if you have it? Joan learns there's no such thing as dry rot, only wet wood that dries out and starts to decay. Shower Renovation: Is flashing needed around a prefabricated shower stall base to prevent moisture issues? Randy should be fine installing the pan over the backer board and adhering tile directly onto the board.   Do you have a home improvement or decor question? Call the show 24/7 at 888-MONEY-PIT (888-666-3974) or post your question here. Learn more about your ad choices. Visit podcastchoices.com/adchoices

January 2023 UAP Round Table with UFO Thinker & PotP - Mosul Orb, The 2022 UAP report, San Marino, NIM Flying Saucer Patch updatesHere is this month's roundtable discussion in conjunction with Frank @UFO Thinker Podcast and we're joined by Dave and Ash (UK UAP) for this one too. We discussed The Mosul Orb, The 2022 UAP report, San Marino, as well as a few other bits along the way.hope you enjoy! you can find us on twitter- Frank @UFOthinker Ash @identifiedUFO Greg @paranormalGregT Dave @dsmethurst66 Ash @UK_UAP

A new whistleblower law in the US, following last year's historic disclosures by the Pentagon, could trigger an avalanche of truths about extraterrestrial activity. ”We have been lied to for 75 years”, says British UFO expert Gary Heseltine. Gary began his UFO investigations–which were then unofficial–when he was still a police detective. In 2013 he left the police force and launched the online magazine UFO Truth Magazine. ”I've made my passion into my job.” This passion has its roots in a strange experience he had when he was 16. He then saw a strange white light that appeared to trigger a number of power cuts in the area where he was living. Following the light, he was able to predict the cuts. Today, Gary Heseltine is also the vice president of ICER, the International Coalition for Extraterrestrial Research. ”It is a mixture of UFO experts, scientists and academics, which is a very unusual mix in this subject”, Gary says. This episode is recorded in Cusco, Peru, with its many mysteriously advanced megalithic structures. Gary is open to the possibility that these structures were built with extraterrestrial help, possibly thousands of years ago, but he and ICER concentrate on UFO sightings during the modern era, basically from 1947 onwards. 1947 was the year of the famous Roswell incident, the event that kicked off the UFO discussion in the modern era. To Gary, there is no doubt Roswell was real. ”We will never prove they retrieved bodies. But we suspect they did.” ”Personally I believe the US government has lied to the public. There has been a campaign of disinformation–maybe for our benefit, but the bottom line is you can't keep lying. I think due to technology we're close to them losing control.” ICER's broader aim is to prepare people for such a coming paradigm shift: the E.T. Disclosure with a big D, when the media will report 24/7 about a nonhuman presence on planet Earth. ”The world is vastly underprepared”, Gary says. ”Considering what's taking place in America, it's a real possibility that there will be an acknowledgement within the next two years that we are dealing with a nonhuman interaction. But this subject has been so ridiculed for so long, so there will be a culture shock if we are not careful.” According to Heseltine, he and others in the coalition have meetings with diplomats behind the scenes. In June of 2021, the Pentagon released three videos of unidentified aerial phenomena (UAPs) and a briefing admitting to 143 unexplained encounters with UAPs. Legislation is in the pipeline entailing that the intelligence community must produce yearly reports about UAP sightings to the Congress plus a right for whistleblowers in the military and intelligence organizations to come forward without reprisals. To Gary Heseltine, this development is a historic game changer. ”For example, the public will be able to hear direct testimony for the first time from people who have been involved in nuclear weapon shutdowns by UFO intervention, like captain Robert Salas was in 1967.” What are we then seeing in the Pentagon clips? Who is visiting us? ”We believe we are dealing with something nonhuman. When you look at the broad abduction scenario across the world, there are at least five main species that seem to be identified. I think governments, especially the Americans, know a hell of a lot more than they say”, Gary says. When the truth comes out, some people will be scared or even panic. ”Because they've been lied to for 75 years, a proportion of the population will feel very vulnerable”, Gary thinks. ”We need to start preparing the public for what will be a huge shock. People could become very angry.”

¿Qué pasó con el Ovni de China de 2009? Se vió desde un observatorio y no hubo más respuestas... Además, ¿Cónoces el ICER? Hablamos con Paolo Guizzardi, uno de sus miembros. Ellos quieren llevar el debate sobre los ovnis a los estratos más altos de la política internacional, esucha!

James Maple, sitting in for Amy, and Patrick present the audio from BloodStream's Diversity, Equity, and Inclusivity panel during National Hemophilia Foundation's Bleeding Disorders Conference as well as the latest from the Let's Talk mental health segment. Plus, news from ICER on gene therapy!   Show Notes: Subscribe: The BloodStream Podcast   Article: Hemophilia gene therapies from BioMarin, CSL pick up an early ICER endorsement    Presenting Sponsor: - Takeda, visit bleedingdisorders.com to learn more.   Episode and Segment Sponsors: - CSL Behring, visit HemEvolution.com to learn more about gene therapy, or ProtraitsofProgress.com for a virtual photo exhibition chronicling hemophilia's history - Sanofi, visit ShareYourWhy.com to meet the CoRe team and hear stories from the hemophilia community. - Pfizer, if you have sickle cell disease, how often do painful crises have you visiting the doctor? Learn more at ClinicalTrialSCD.com    Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter 

This week Jeremy revisits testimony provided by ALS advocates and ALS Association leaders at a recent public forum to consider ICER's flawed analysis of AMX0035 and oral edaravone. Watch the public forum in its entirety at https://www.youtube.com/watch?v=iqmXcxgkMPY&t=13s Learn more about the fight for access to therapies at als.org/icer Learn more about Steve Kowalski at https://www.als.org/blog/theres-still-lot-life-be-lived-steve-kowalskis-story Read some of Sunny's story at https://www.als.org/blog/sunny-brous-erasmus-long-were-here-were-together Follow Sunny's journey at https://sunnystrong.com/This episode is brought to you by The ALS Association in partnership with CitizenRacecar.

This week, Jeremy continues his conversation with Dr. Neil Thakur, chief mission officer at The ALS Association, about the latest developments in the fight for approval of and access to AMX0035 and explores the Association's formal objections to ICER's draft analysis.Learn more about efforts to make sure flawed and discriminatory data isn't used to erect barriers to access at als.org/icerThis episode is brought to you by The ALS Association in partnership with CitizenRacecar.

Sheryl has had a life-long interest in the paranormal which began in her teenage years, but in 1980 she began seriously studying the phenomenon of Near Death Experiences. Soon after she joined the International Association for Near Death Studies (IANDs) and in 1995 hosted Dr Ken Ring for the Brisbane leg of his Australian tour where he presented research for his future book Mindsight: Near Death and Out Of Body Experiences In The Blind. She also developed a deep interest in the UFO phenomenon, catalysed by her father-in-laws interest after he attended a UFO meeting hosting George Adamski in the 1960s. In 1988 she joined the Brisbane based Association, UFO Research Queensland, and three years later took on the role of President. Then in 1992, Sheryl and her late husband Dr Martin Gottschall, established the first close encounter support group in Brisbane after Budd Hopkins Australian tour. Dr Rings book The Omega Project: Near Death Experiences, UFO Encounters, and the Mind At Large (1992) ignited Sheryl's interest in the connections between UFOs and NDEs which was now being corroborated by the witnesses she was interviewing. Some years later in 2012, she established the monthly Afterlife Discussions group where she continues to find links between UFOs and the afterlife in the stories shared. Sheryl is also the Australian representative for the recently launched International Coalition for Extraterrestrial Research (ICER), the first truly global international UFO organisation that considers we now need to prepare for confirmation that the Earth is being engaged by non-human intelligences. ICER aims to take this discussion to the highest levels of governance, including the United Nations. Sheryl has had many paranormal experiences herself including an NDE, a bi-location experience, Out of Body experiences (OBE), UFO sightings, a close encounter with non human intelligences (ETs), poltergeist activity, automatic writing, and other unexplained phenomena; all of which propel her to continue on her quest to understand what it means to be human. Sheryl's research bridges the Afterlife and UFO subjects, and wanting to understand the UFO phenomenon more deeply led her to train in shamanism which she now teaches. She speaks regularly about the UFO phenomenon and the Afterlife at public meetings, conferences, community groups, schools, libraries and has given hundreds of media interviews. She has written articles for many UFO and New Age magazines and in 2018 was a regular guest on the weekly Spooky Action radio show and co-hosted the Strange Encounters radio show in 2019. Currently she is a regular writer for the UFO Research Queensland bi-monthly publication, UFO Encounter. Sheryl works as a clinical hypnotherapist, teaches Reiki, art therapy, shamanism and will be launching the Strange Encounters podcast in August 2021. Contact Sheryl at: info@uforq.asn.au ; www.uforq.asn.au ; https://twitter.com/UFOhubnews www.facebook.com/uforesearchqueensland ; www.youtube.com/c/UFOResearchQueensland For more typical skeptic podcast interviews go to: www.youtube.com/c/typicalskeptic www.anchor.fm/typical-skeptic To donate to the typical skeptic podcast you can paypal me typicalskeptic1@gmail.com #NDE #Alien #Encounter #NearDeathExperience #Extraterrestrial #UFO #Podcast --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/typical-skeptic/message Support this podcast: https://anchor.fm/typical-skeptic/support

EPISODE #640 THE INTERNATIONAL COALITION FOR EXTRATERRESTRIAL RESEARCH PT. 2 Richard welcomes the USA Representative for ICER, a not-for-profit organization, comprised of scientists, academics and leading UFO/UAP researchers from 27 countries on 5 continents who are unanimous in their recognition that we are not alone in the cosmos.  Guest: Donald Schmitt is the former co-director of the J. Allen Hynek Center for UFO Studies in Chicago where he served as Director of Special Investigations for 10 years. Prior to that time, he was a special investigator for the late Dr. J. Allen Hynek and the art director for the International UFO Reporter. He is author of hundreds of articles about UFOs as well as the co-author of five best-selling books UFO Crash at Roswell, The Truth About the UFO Crash at Roswell, Witness To Roswell, Witness to Roswell: Revised Addition, and Inside the Real Area 51; The Secret History of Wright Patterson. He is also the author of Roswell, The Chronological Pictorial. SUPPORT OUR SPONSORS!!!   C60EVO -The Secret is out about this powerful anti-oxidant. The Purest C60 available is ESS60.  Buy Direct from the Source.  Buy Now and Save 10% – Use Coupon Code: EVRS at Checkout!   Strange Planet Shop - If you're a fan of the radio show and the podcast, why not show it off?  Greats T-shirts, sweatshirts, mugs, and more.  It's a Strange Planet - Dress For It! BECOME A PREMIUM SUBSCRIBER FOR LESS THAN $2 PER MONTH If you're a fan of this podcast, I hope you'll consider becoming a Premium Subscriber.  For just $1.99 per month, subscribers to my Conspiracy Unlimited Plus gain access to two exclusive, commercial-free episodes per month. They also gain access to my back catalog of episodes. The most recent 30 episodes of Conspiracy Unlimited will remain available for free.  Stream all episodes and Premium content on your mobile device by getting the FREE Conspiracy Unlimited APP for both IOS and Android devices... Available at the App Store and Google Play.

EPISODE #639 THE INTERNATIONAL COALITION FOR EXTRATERRESTRIAL RESEARCH PT. 1 Richard welcomes the Vice President of ICER, a not-for-profit organization, is comprised of scientists, academics and leading UFO/UAP researchers from 27 countries on 5 continents who are unanimous in their recognition that we are not alone in the cosmos. Based on more than 75 years of research, ICER acknowledges that the UFO/UAP phenomenon is real; it acts with intelligence and is likely to be extraterrestrial/non-human in origin. ICER believes all countries now need to prepare for confirmation that the Earth is being engaged by non-human intelligences and proposes 'awareness' programs be established to deal with the profound issue of Contact and its global implications. Gary Heseltine is Vice President of the International Coalition for Extraterrestrial Research (ICER) composed of scientists, academics and leading UFO/UAP researchers worldwide. The organization launched in May 2021. Using skills finely honed as a Home Office-trained police officer, Gary has examined cases with the "best evidence", those that have high caliber witnesses with special knowledge, often corroborated by technology. He concludes, on "circumstantial evidence", that some unidentified objects act as if intelligently-controlled, and that whatever is behind them is likely to be extraterrestrial, or non-human. While an officer he created, in 2002, an unofficial national database recording police sightings: PRUFOS (Police Reporting UFO Sightings). The database collates police sightings from sources including newspaper archives and Ministry of Defence documents.   SUPPORT OUR SPONSORS!!!   C60EVO -The Secret is out about this powerful anti-oxidant. The Purest C60 available is ESS60.  Buy Direct from the Source.  Buy Now and Save 10% – Use Coupon Code: EVRS at Checkout!   Strange Planet Shop - If you're a fan of the radio show and the podcast, why not show it off?  Greats T-shirts, sweatshirts, mugs, and more.  It's a Strange Planet - Dress For It! BECOME A PREMIUM SUBSCRIBER FOR LESS THAN $2 PER MONTH If you're a fan of this podcast, I hope you'll consider becoming a Premium Subscriber.  For just $1.99 per month, subscribers to my Conspiracy Unlimited Plus gain access to two exclusive, commercial-free episodes per month. They also gain access to my back catalog of episodes. The most recent 30 episodes of Conspiracy Unlimited will remain available for free.  Stream all episodes and Premium content on your mobile device by getting the FREE Conspiracy Unlimited APP for both IOS and Android devices... Available at the App Store and Google Play. To become a subscriber CLICK HERE or go to www.conspiracyunlimitedpodcast.com and click on Get Access to Premium Episodes